menu search

mersana therapeutics to host third quarter 2023 conference call on november 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinic...

October 31, 2023, 4:30 pm

After plunging -68.18% in 4 weeks, here's why the trend might reverse for mersana therapeutics, inc. (mrsn)

The heavy selling pressure might have exhausted for mersana Therapeutics, Inc. (MRSN) as it is technica...

August 18, 2023, 11:05 am

Down -64.71% in 4 weeks, here's why mersana therapeutics, inc. (mrsn) looks ripe for a turnaround

The heavy selling pressure might have exhausted for mersana Therapeutics, Inc. (MRSN) as it is technica...

August 16, 2023, 10:59 am

mersana therapeutics, inc. (mrsn) reports q2 loss, misses revenue estimates

mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.47 per share versus the Zacks Co...

August 8, 2023, 11:25 am

Ecor1 capital, llc acquires significant stake in mersana therapeutics inc

San Francisco-based investment firm, EcoR1 Capital, LLC (Trades, Portfolio), recently executed a significant transaction involving the acquisition of ...

July 27, 2023, 8:34 pm

mersana therapeutics announces topline data from uplift clinical trial in patients with platinum-resistant ovarian cancer and strategic reprioritization

UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026 Conf...

July 27, 2023, 11:06 am

Shareholder alert: pomerantz law firm investigates claims on behalf of investors of mersana therapeutics, inc. – mrsn

NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of m...

June 17, 2023, 5:17 pm

mersana (mrsn) down on partial ovarian cancer study hold

mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies ev...

June 16, 2023, 12:20 pm

mersana therapeutics announces partial clinical hold on up-next and upgrade-a clinical trials

UPLIFT top-line data expected by early August CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) — mersana...

June 15, 2023, 11:30 am

mersana therapeutics shares tank as fda puts ovarian cancer drug trials on partial hold

mersana Therapeutics (NASDAQ:MRSN) stock plummeted more than 60% on Thursday after the clinical-stage b...

June 15, 2023, 10:18 am

Us fda puts mersana therapeutics' ovarian cancer drug studies on partial hold

mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial...

June 15, 2023, 8:03 am

mersana therapeutics to present at upcoming investor conferences

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) — mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinic...

May 24, 2023, 12:00 pm

mersana therapeutics: unrecognized promise in upri's cancer fight

Concerns related to safety risks around ILD/pneumonitis are overblown in a disease of high unmet needs. I believe clinical benefits outweigh potential...

April 3, 2023, 5:20 pm

mersana therapeutics provides statement about svb

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) — mersana Therapeutics, Inc. (NASDAQ: MRSN), a clin...

March 11, 2023, 12:10 am

mersana therapeutics, inc. (mrsn) q4 2022 earnings call transcript

mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET...

February 28, 2023, 10:50 am

mersana: i like the science, derisking will come from more proof

mersana has excellent ADC science. A number of big pharma have bought into the science....

January 23, 2023, 4:29 am

mersana therapeutics, inc. (mrsn) ceo anna protopapas on q2 2022 results - earnings call transcript

mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Co...

August 8, 2022, 10:36 pm

mersana therapeutics, inc. (mrsn) reports q2 loss, tops revenue estimates

mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respecti...

August 8, 2022, 6:48 pm

mersana therapeutics, inc. (mrsn) ceo anna protopapas on q4 2021 results - earnings call transcript

mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call Transcript...

February 28, 2022, 11:25 am


Search within

Pages Search Results: